SEARCH

SEARCH BY CITATION

LITERATURE CITED

  • 1
    CristofanilliM,BuddGT,EllisMJ,StopeckA,MateraJ,MillerMC,RuebenJMDoyleG,AllardWJ,TerstappenLWMM, et al. Circulating tumor cells, disease progression and survival in metastatic breast cancer.NEJM 2004;351:781791.
  • 2
    LiuMC,ShieldsPG,WarrenRW,CohenP,WilkinsonM,OttavianoYL,RaoSB,Eng-WongJ,Seillier-MoiseiwitschF,NooneAM, et al. Circulating tumor cells: A useful predictor of treatment efficacy in metastatic breast cancer.JCO 2009;27:51535159.
  • 3
    CohenSJ,PuntCJA,IannottiN,SaidmanBH,SabbathKD,GabrailNY,PicusJ,MorseM,MitchellE,MillerMC, et al. The relationship of circulating tumor cells to tumor response, progression-free survival, and overall survival in patients with metastatic colorectal cancer.JCO 2008;26:32133221.
  • 4
    TolJ,KoopmanM,MillerMC,TibbeA,CatsA,CreemersGJM,VosAH,NagtegaalID,TerstappenLWMM,PuntCJA.Circulating tumour cells early predict progression-free and overall survival in advanced colorectal cancer patients treated with chemotherapy and targeted agents.Ann Oncol 2010;21:10061012.
  • 5
    DeBonoJS,ScherHI,MontgomeryRB,ParkerC,MillerMC,TissingH,DoyleGV,TerstappenLWMM,PientaKJ,RaghavanD.Circulating tumor cells (CTC) predict survival benefit from treatment in metastatic castration resistant prostate cancer (CRPC).Clin Can Res 2008;14:63026309.
  • 6
    OlmosD,ArkenauHT,AngJE,LedakiI,AttardG,CardenCP,ReidAHM,HemRA,FongPC,OomenNB, et al. Circulating Tumor Cells (CTC) as intermediate end points in castration-resistant prostate cancer (CRPC): A single-centre experience.Ann Oncol 2009;20:2737.
  • 7
    NagrathS,SequistLV,MaheswaranS,BellDW,IrimiaD,UlkusL,SmithMR,KwakEL,DigumarthyS,MuzikanskyA, et al. Isolation of rare circulating tumour cells in cancer patients by microchip technology.Nature 2007;450:12351241.
  • 8
    PachmannK,CamaraO,KavallarisA,KrauspeS,MalarskiN,GajdaM,KrollT,JörkeC,HammerU,Altendorf-HofmannA, et al. Monitoring the response of circulating epithelial tumor cells to adjuvant chemotherapy in breast cancer allows detection of patients at risk of early relapse.JCO 2008;26:12081215.
  • 9
    KahnHJ,PrestaA,YangLY,BlondalJ,TrudeauM,LickleyL,HollowayC,McCreadyDR,MacleanD,MarksA.Enumeration of circulating tumor cells in the blood of breast cancer patients after filtration enrichment: Correlation with disease stage.Breast Cancer Res Treat 2004;86:237247.
  • 10
    KrivacicRT,LadanyiA,CurryDN,HsiehHB,KuhnP,BergsrudDE,KeprosJF,BarberaT,HoMY,ChenLB, et al. A rare-cell detector for cancer.Proc Natl Acad Sci USA 2004;101:1050110504.
  • 11
    HsiehHB,MarrinucciD,BethelK,CurryDN,HumphreyM,KrivacicRT,KroenerJ,KroenerL,LadanyiA,LazarusN, et al. High speed detection of circulating tumor cells.Biosens Bioelectron 2006;21:18931899.
  • 12
    RacilaE,EuhusD,WeissAJ,RaoC,McConnellJ,TerstappenLWMM,UhrJW.Detection and characterization of carcinoma cells in the blood.Proc Natl Acad Sci USA 1998;95:45894594.
  • 13
    CoumansF,DoggenCJM,AttardG,de BonoJS,TerstappenLWMM.All circulating EpCAM+CD45-CK+ but not EpCAM+CD45+CK+ objects predict overall survival in castration-resistant prostate cancer.Ann Oncol 2010;21:18511857.
  • 14
    AllardWJ,MateraJ,MillerMC,RepolletM,ConnellyMC,RaoC,TibbeA,UhrJW,TerstappenLWMM.Tumor cells circulate in the peripheral blood of all major carcinomas but not in healthy subjects or patients with non-malignant diseases.Clin Can Res 2004;10:68976904.
  • 15
    KaganM,HowardD,BendeleT,MayesJ,SilviaJ,RepolletM,DoyleJ,AllardJ,TuN,BuiT, et al. A sample preparation and analysis system for identification of circulating tumor cells.J Clinical Ligand Assay 2002;25:104110.
  • 16
    TibbeAGJ,MillerC,TerstappenLWMM.Statistical considerations for enumeration of circulating tumor cells.Cytometry Part A 2007;71A:154162.
  • 17
    LarsonCJ,MorenoJG,PientaKJ,GrossS,RepolletM,O'HaraSM,RussellT,TerstappenLWMM.Apoptosis of circulating tumor cells in prostate cancer patients.Cytometry Part A 2004;62A:4653.
  • 18
    ScholtensTM,SchreuderF,LigthartST,SwennenhuisJF,TibbeAGJ,GreveJ,TerstappenLWMM.CellTracks TDI: An image cytometer for cell characterization.Cytometry Part A 2011;79A:203213.
  • 19
    SchreuderF. Laser Image Cytometer for Analysis of Circulating Tumor Cells. ISBN 978-90-365-2610-4, January 2008 (Thesis).
  • 20
    TibbeAGJ,de GroothBG,GreveJ,DolanGJ,RaoC,TerstappenLWMM.Magnetic field design for selecting and aligning immunomagnetic labeled cells.Cytometry 2002;47:163172.
  • 21
    OrtynWE,HallBE,GeorgeTC,FrostK,BasijiDA,PerryDJ,ZimmermanCA,CoderD,PhilipJ,MorrisseyPJ.Sensitivity measurement and compensation in spectral imaging.Cytometry Part A 2006;69A:852862.
  • 22
    RasbandWS.ImageJ.Maryland, USA:US National Institutes of Health, Bethesda. http://rsb.info.nih.gov/ij/ 1997-2011.
  • 23
    AbramoffMD,MagelhaesPJ,RamSJ.Image processing with ImageJ.Biophoton Int 2004;11:3642.
  • 24
    LiaoPS,ChenTS,ChungPC.A fast algorithm for multilevel thresholding.J Info Sci Eng 2001;17:713727.
  • 25
    BreimanL.Bagging predictors.Mach Learn 1996;24:123140.
  • 26
    BreimanL.Random forests.Mach Learn 2001;45:532.
  • 27
    WuB,AbbottT,FishmanD,McMurrayW,MorG,StoneK,WardD,WilliamsK,ZhaoH.Comparison of statistical methods for classification of ovarian cancer using mass spectrometry data.Bioinformatics 2003;19:16361643.
  • 28
    GislasonPO,BenediktssonJA,SveinssonJR.Random forests for land cover classification.Pattern Recog Lett 2006;27:294300.
  • 29
    HoTK.The random subspace method for constructing decision forests.IEEE Trans Pattern Anal Mach Intell 1998;20:832844.
  • 30
    HamJ,ChenY,CrawfordMM,GhoshJ.Investigation of the random forest framework for classification of hyperspectral data.IEEE Trans Geosci Remote Sens 2005;43:492501.
  • 31
    GengW,CosmanP,BerryCC,FengZ,SchaferWR.Automatic tracking, feature extraction and classification of C. elegans phenotypes.IEEE Trans Biomed Eng 2004;51:18111820.
  • 32
    RamírezJ,GórrizJM,ChavesR,LópezM,Salas-GonzalezD,ÁlvarezI,SegoviaF.SPECT image classification using random forests.Electron Lett 2009;45:604605.
  • 33
    KovalevV,HarderN,NeumannB,HeldM,LiebelU,ErfleH,EllenbergJ,EilsR,RohrK.Feature selection for evaluating fluorescence microscopy images in genome-wide cell screens.Proceedings of the IEEE Computer Society Conference on Computer Vision and Pattern Recognition 2006;1:276283.
  • 34
    NewbergJY,LiJ,RaoA,PontenF,UhlenM,LundbergE,MurphyRF.Automated analysis of human protein atlas immunofluorescence images.Proceedings of the IEEE Int Symp Biomed Imag 2009;10231026.
  • 35
    KhoshgoftaarTM,GolawalaM,Van HulseJ. An empirical study of learning from imbalanced data using random forest. 19th IEEE International Conference on Tools with Artificial Intelligence2007;2:310317.
  • 36
    LandisJR,KochGG.The measurement of observer agreement for categorical data.Biometrics 1977;33:15974.
  • 37
    CohenJ.Weighted kappa: Nominal scale agreement provision for scaled disagreement or partial credit.Psychol Bull 1968;70:213220.
  • 38
    SimJ,WrightCC.The Kappa statistic in reliability studies: Use, interpretation, and sample size requirements.Phys Ther 2005;85:257268.
  • 39
    FleissJL.Measuring nominal scale agreement among many raters.Psychol Bull 1971;76:378382.
  • 40
    AttardG,SwennenhuisJF,OlmosD,ReidAHM,VickersE,A'HernR,LevinkR,CoumansF,MoreiraJ,RiisnaesR, et al. Characterization of ERG, AR and PTEN status in circulating tumor cells from patients with castration-resistant prostate cancer.Cancer Res 2009;69:29122918.
  • 41
    SwennenhuisJF,TibbeAGJ,LevinkR,SipkemaRCJ,TerstappenLWMM.Characterization of circulating tumor cells by fluorescence in-situ hybridization.Cytometry Part A 2009;75A:520527.
  • 42
    RaoCG,ChianeseD,DoyleGV,MillerMC,RussellT,SandersRA,TerstappenLWMM.Expression of epithelial cell adhesion molecule in carcinoma cells present in blood and primary and metastatic tumors.Int J Oncol 2005;27:4958.
  • 43
    LeersMPG,BjörklundV,BjörklundB,JörnvallH,NapM.An immunohistochemical study of the clearance of apoptotic cellular fragments.Cell Mol Life Sci 2002;59:13581365.
  • 44
    KuN,LiaoJ,OmaryMB.Apoptosis generates stable fragments of human type I keratins.J Bio Chem 1997;272:3319733203.
  • 45
    WangZP,EisengbergerM,CarducciM,PartinA,ScherH,Ts'oPOP.Identification and characterization of circulating prostate carcinoma cells.Cancer 2000;88:27872795.
  • 46
    MehesG,WittA,KubistaE,AmbrosP.Circulating breast cancer cells are frequently apoptotic.Am J Pathol 2001;159:1720.
  • 47
    HäggM,BivenK,UenoT,RydlanderL,BjörklundP,WimanKG,ShoshanM,LinderS.A novel high-through-put assay for screening of pro-apoptotic drugs.Invest New Drugs 2002;20:253259.
  • 48
    SchutteB,HenflingM,KolgenW,BoumanM,MeexS,LeersMPG,NapM,BjörklundV,BjörklundP,BjörklundB, et al. Keratin 8/18 breakdown and reorganization during apoptosis.Exp Cell Res 2004;297:1126.
  • 49
    KramerG,ErdalH,MertensHJMM,NapM,MauermannJ,SteinerG,MarbergerM,BivenK,ShoshanMC,LinderS.Differentiation between cell death modes using measurements of different soluble forms of extracellular cytokeratin 18.Cancer Res 2004;64:17511756.
  • 50
    JahrS,HentzeH,EnglischS,HardtD,FackelmayerFO,HeschR,KnippersR.DNA fragments in the blood plasma of cancer patients: Quantitations and evidence for their origin from apoptotic and necrotic cells.Cancer Res 2001;61:16591665.
  • 51
    OlofssonMH,UenoT,PanY,XuR,CaiF,van der KuipH,MuerdterTE,SonnenbergM,AulitzkyWE,SchwarzS, et al. Cytokeratin-18 is a useful serum biomarker for early determination of response of breast carcinomas to chemotherapy.Clin Cancer Res 2007;11:31983206.
  • 52
    LaiRS,HsuHK,LuJY,GerLP,LaiNS.CYFRA 21-1 enzyme-linked immunosorbent assay evaluation as a tumor marker in non-small cell lung cancer. Chest 1996;109:9951000.
  • 53
    Alix-PanabieresC,BrouilletJP,FabbroM,YsselH,RoussetT,MaudelondeT,Choquet-KastylevskyG,VendrellJP.Characterization and enumeration of cells secreting tumor markers in the peripheral blood of breast cancer patients.J Immunol Methods 2005;299:177188.
  • 54
    KahnHJ,PrestaA,YangLY,BlondalJ,TrudeauM,LickleyL,HollowayC,McCreadyDR,MacleanD,MarksA.Enumeration of circulating tumor cells in the blood of breast cancer patients after filtration enrichment: Correlation with disease stage.Breast Cancer Res Treat 2004;86:237247.
  • 55
    KrivacicRT,LadanyiA,CurryDN,HsiehHB,KuhnP,BergsrudDE,KeprosJF,BarberaT,HoMY,ChenLB, et al. A rare-cell detector for cancer.Proc Natl Acad Sci USA 2004;101:1050110504.
  • 56
    VonaG,SabileA,LouhaM,SitrukV,RomanaS,SchutzeK,CapronF,FrancoD,PazzagliM,VekemansM, et al. Isolation by size of epithelial tumor cells: A new method for the immunomorphological and molecular characterization of circulating tumor cells.Am J Pathol 2000;156:5763.
  • 57
    GleghornJP,PrattED,DenningD,LiuH,BanderNH,TagawaST,NanusDM,GiannakakouPA,KirbyBJ.Capture of circulating tumor cells from whole blood of prostate cancer patients using geometrically enhanced differential immunocapture (GEDI) and a prostate-specific antibody.Lab on a Chip - Miniaturisation for Chemistry and Biology 2010;10:2729.
  • 58
    KönigsbergR,ObermayrE,BisesG,PfeilerG,GneistM,WrbaF,De SantisM,ZeillingerR,HudecM,DittrichC.Detection of EpCAM positive and negative circulating tumor cells in metastatic breast cancer patients.Acta Oncol 2011;50:700710.
  • 59
    GascoynePRC,NoshariJ,AndersonTJ,BeckerFF.Isolation of rare cells from cell mixtures by dielectrophoresis.Electrophoresis 2009;30:13881398.
  • 60
    TanSJ,LakshmiRL,ChenP,LimWT,YobasL,LimCT.Versatile label free biochip for the detection of circulating tumor cells from peripheral blood in cancer patients.Biosensors and Bioelectronics 2010;26:17011705.